Applicability of mitochondrial energy factors in accompanying therapy of lymphoproliferative diseases (experimental study)

Автор: Elena M. Frantsiyants, Irina V. Kaplieva, Valerija A. Bandovkina, Lidia K. Trepitaki, Ekaterina I. Surikova, Irina V. Neskubina, Julija A. Pogorelova, Natalia D. Cheryarina, Alla I. Shikhlyarova, Tat’jana I. Moiseenko, Maxim N. Duritskii, Sergey V. Tumanian, Yuriy V. Przhedetskiy, Viktoria V. Pozdnyakova

Журнал: Cardiometry @cardiometry

Рубрика: Original research

Статья в выпуске: 20, 2021 года.

Бесплатный доступ

Aim. The purpose of the study was to reveal the effectiveness of the Cytochrome C drug in the early stages of the Pliss lymphosarcoma growth in white outbred rats. Material and methods. The studies were included white outbred male rats with an initial weight of 180–220 g (n = 40) with subcutaneously inoculated Pliss lymphosarcoma. Rats in the main group received the Cytochrome C intraperitoneally in a single dose of 1.6 mg/kg 1 hour after the tumor inoculation and then until death; animals with tumors in the control group received saline instead of the studied drug in the same way and in the same dosage. Results. Subcutaneous tumors appeared in the control group in 100% cases, in the main group in 55% cases; tumors were not detected in 45% of animals in the main group. In rats of the main group receiving experimental treatment, tumors regressed with time: in 73% cases with complete recovery of rats, in 27% cases animals died. Conclusions. The Cytochrome C in a therapeutic and prophylactic regimen had a pronounced antitumor effect. Perhaps the effectiveness of the drug can be improved using an inert carrier which will protect the protein from proteolytic cleavage when it enters the bloodstream, together with detoxification agents.

Еще

Pliss lymphosarcoma, Cytochrome C, Rats, Tumors, Survival

Короткий адрес: https://sciup.org/148322429

IDR: 148322429   |   DOI: 10.18137/cardiometry.2021.20.2933

Список литературы Applicability of mitochondrial energy factors in accompanying therapy of lymphoproliferative diseases (experimental study)

  • Chowdhury SR, Ray U, Chatterjee BP, Roy SS. Targeted apoptosis in ovarian cancer cells through mitochondrial dysfunction in response to Sambucus nigra agglutinin. Cell Death Dis. 2017; 8(5): e2762. doi: 10.1038/cddis.2017.77.
  • Nakhle J, Rodriguez AM, Vignais ML. Multifaceted Roles of Mitochondrial Components and Metab-Table 3 Dynamics of PTGI and γ in rats with Pliss lymphosarcoma Day of the experiment Coefficients 8 10 13 16 20 23 PTGI, % – 267.65 0 11.40 3.13 55.11 67.79 γ, arb.u. 7.50 15.63 6.77 19.27 35.99 33.14 Issue 20. November 2021 | Cardiometry | 33 olites in Metabolic Diseases and Cancer. International journal of molecular sciences. 2020;21(12): 4405. https://doi.org/10.3390/ijms21124405.
  • Roth KG, Mambetsariev I, Kulkarni P, Salgia R. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in molecular medicine. 2020; 26(1): 119– 134. https://doi.org/10.1016/j.molmed.2019.06.009
  • Toth A, Aufschnaiter A, Fedotovskaya O, Dawitz H, Ädelroth P, Büttner S, Ott M. Membrane-tethering of cytochrome c accelerates regulated cell death in yeast. Cell Death Dis. 2020 11(9): 722. doi: 10.1038/s41419-020-02920-0.
  • Francijanc EM, et al. Functional state of mitochondria of cardiomyocytes in the malignant process against the background of comorbid pathology in the experiment. Juzhno-rossijskij onkologicheskij zhurnal. 2021; 2(3): 13-22. [in Russian]
  • da Veiga Moreira J, Schwartz L, Jolicoeur M. Targeting Mitochondrial Singlet Oxygen Dynamics Offers New Perspectives for Effective Metabolic Therapies of Cancer. Frontiers in oncology. 2020; 10: 573399. https://doi.org/10.3389/fonc.2020.573399
  • Sidorenko JuS, Kartashov SZ, Francijanc EM. A method for treating lung cancer. Patent na izobretenie RU 2123342 C1, 20.12.1998. Application No. 95115286/14, August 29, 1995. [in Russian]
  • Kit OI, et al. A method for preventing the development of a malignant process in an experiment Pat. 2 559 286 Rossijskaja Federacija MPK A61K, A61P. / zajavitel’ i patentoobladatel’ RNIOI (RU). № 2014103403; submitted January 31, 2014; published August 10, 2015, Bjul. No. 22. [in Russian]
Еще
Статья научная